OverviewChartNewsTraderScreen

Clinuvel Pharmaceuticals Ltd./  US1887691038  /

Nasdaq Other OTC
2024-05-20  4:10:42 PM Chg. -0.0900 Volume Bid- Ask- High Low
10.1600USD -0.88% 325
Turnover: 3,056		 -Bid Size: - -Ask Size: - 10.2000 10.1600
GlobeNewswire 2021-11-08 CLINUVEL Expands Pharmaceutical Portfolio
GlobeNewswire 2021-03-24 CLINUVEL expands DNA Repair Program
GlobeNewswire 2020-10-27 CLINUVEL to Trial Innovative Drug in Stroke
GlobeNewswire 2020-09-15 First patient dosed in SCENESSE® DNA Repair Program
GlobeNewswire 2020-09-10 CLINUVEL progresses innovative DNA Repair Program
GlobeNewswire 2020-08-31 CLINUVEL Opens VALLAURIX R&D Centre In Singapore
GlobeNewswire 2020-07-13 PRÉNUMBRA® - CLINUVEL's Second Afamelanotide Formulation
GlobeNewswire 2020-04-23 SCENESSE® to be Prescribed in China
GlobeNewswire 2020-04-16 Innovative drug launched for rare, isolating, “light intolerance” disorder
GlobeNewswire 2019-10-09 FDA Approves SCENESSE® For Genetic Disorder
GlobeNewswire 2019-06-03 US FDA Review for SCENESSE® Extended by Three Months
GlobeNewswire 2019-01-10 US FDA sets PDUFA date for SCENESSE®
GlobeNewswire 2018-12-19 Phase II study: SCENESSE® in combination with narrowband ultraviolet B (NB-UVB) achieves repigmentat...
GlobeNewswire 2018-08-29 CLINUVEL delivers second positive financial result
GlobeNewswire 2018-06-25 FDA to Review Australian Drug for Genetic Disorder of Absolute Light Intolerance
GlobeNewswire 2018-02-20 CLINUVEL unveils new global positioning
GlobeNewswire 2018-01-22 Nasdaq Welcomes Cielo S.A. to the Nasdaq International Designation
GlobeNewswire 2018-01-22 Nasdaq Welcomes Cielo S.A. to the Nasdaq International Designation
GlobeNewswire 2017-04-12 CLINUVEL reaches agreement on German SCENESSE® pricing through AMNOG Arbitration Board
GlobeNewswire 2016-06-01 Nasdaq Welcomes Additional Companies to the Nasdaq International Designation